Roche launches new process for accessing clinical trial data

RocheRoche is expanding access to its clinical trial data for third party researchers. Roche will work with an independent body of recognised experts to evaluate and approve requests to access anonymised patient-level data. Roche will support the release of full clinical study reports (CSRs) for all its licensed medicines via regulatory authorities and make available any CSRs that cannot be provided by these authorities upon a researcher’s request.

"We understand and support calls for our industry to be more transparent about clinical trial data with the aim of meeting the best interests of patients and medicine," said Daniel O'Day, Chief Operating Officer of Roche Pharma. "At the same time, we firmly believe that health authorities need to remain the gatekeeper for drug assessment and approval. We believe we have found a way in which patient data can be provided to third party researchers in a legitimate environment that ensures patient confidentiality and avoids the risk of publishing misleading results or giving rise to public health scares and consequences."

Roche continues to provide all information requested by health authorities who approve medicines for patient use. Public access to results from clinical trials is also provided via rochetrials.com and clinicaltrials.gov in a summary form. Roche will also submit results to the European Union database, EudraCT as soon as this public archive becomes operational.

Roche is supporting the European Medicines Agency (EMA) in its commitment to the proactive publication of data from all clinical trials supporting the authorisation of medicines. Roche is a member of one of the EMA advisory groups working on the new EMA data access guidelines. The policy is scheduled to come into force early 2014.

Amendments to the Roche data transparency policy include:

Access to patient data sets: An independent body will assess the scientific validity of requests for anonymised patient-level data, with the requested data made available within a secure system following agreement. Access to patient data will be available for those clinical trials which have been submitted together with an application for a medicine's registration and will be available after the completion of regulatory reviews in the U.S. and European Union. This process will come into effect in 2013. Roche is in discussions with other pharmaceutical companies to see if this can be an industry-wide initiative.

Access to CSRs: Roche supports the release of full CSRs, summaries and safety updates for its approved medicines by the EMA. In line with relevant country or regional laws, this information will be edited in consultation with Roche to ensure patient confidentiality and to protect legitimate commercial interests, including intellectual property rights. Roche will provide any CSR on request that cannot be obtained from the EMA for third party researchers with this specific process coming into effect by April 2013. This will enable access to all Roche CSRs for researchers.

Tamiflu (oseltamivir) data
Roche acknowledges the specific public interest in data transparency concerning the antiviral Tamiflu. Health authorities worldwide have received all the information they have requested regarding Tamiflu.

Of 74 completed Roche sponsored Tamiflu trials, 71 (or 96%) are in the public domain either as a primary publication or secondary publication or on rochetrials.com. Arrangements are underway for the three sponsored trials which are completed but not yet in the public domain to be posted.

Roche supports a fair, transparent and independent way of addressing data transparency regarding Tamiflu. To do this, a MUlti-party Group for Advice on Science (MUGAS) will be set up by four renowned scientists in the field of influenza to look at data on Tamiflu, identify any unanswered questions and agree on a statistical analysis plan. Following an agreement, Roche will provide access to all requested Tamiflu clinical trial data for the analyses.

The four scientists will invite independent experts and third parties to their meeting, which is scheduled to take place in June. The four scientists are Prof Albert Osterhaus, Erasmus Medical Centre Rotterdam; Prof Menno De Jong, Academic Medical Centre Amsterdam; Prof Arnold Monto, University of Michigan and Prof Richard Whitley, University of Alabama.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...